BRAF and neoplasm: BRAF inhibitor-based targeted therapy, such as vemurafenib and dabrafenib, has significantly enhanced the tumor response and progression-free survival (PFS) for patients with metastatic melanoma who also have an activating BRAF mutation (19, 20).